Method of predicting duration of recurrence-free period in radically treated patients with mammary gland cancer |
|||||||||||||||||||||||
|
IPC classes for russian patent Method of predicting duration of recurrence-free period in radically treated patients with mammary gland cancer (RU 2413231):
Method of predicting of process activation in patients with hodgkin's lymphoma / 2405454
Invention relates to medicine, namely to biochemical investigations in oncology, and can be used in determination of activation or stabilisation of pathologic process in patients with primary-resistant Hodgkin's lymphoma. In patients with primary-resistant Hodgkin's lymphoma at stages of treatment, by radioimmune method determined is content in blood of thyroid gland hormones - triiodothyronine and thyroxine, and adrenocortical hormone - cortisol, their concentration is summed up and in case of total level of hormones is within 278.2 nmole/l - 0 333.0 nmole/l conclusion about activation of malignant process is made, if total level of said hormones is 432.4 nmole/l - 833.2 nmole/l conclusion about absence of process activation is made.
Diagnostic technique for severity level of varicocele and its recuring / 2403871
Invention refers to medicine, namely to urology and vascular surgery. The sex hormones level in an involved vein is considered to be a criterion of the severity level of varicocele. There are evaluated the following sex hormones: testosterone, estradiol, progesterone simultaneously in the pampiniform plexus veins of a left ovary and in the peripheral vein of a bend of elbow, with determining the ratio of the sex hormones level in a healthy vein of the bend of elbow to the varicocele-involved pampiniform plexus vein. If said ratio of the sex hormones level is 1:10 to 1:50, the first degree of varicocele is diagnosed. Recurrent varicocele and the second degree of varicocele is diagnosed by the ratio of the sex hormones level in the healthy and involved veins 1:50 to 1:100 times (i.e. hormones concentration in a varicose vein is increased in tens times). If observing the ratio of the sex hormones level in the healthy vein and the involved vein of the pampiniform plexus veins of the left ovary increasing more than in 1:100, the third degree of varicocele is diagnosed. Surgical intervention is indicated if the ratio of the sex hormones level is diagnosed more than 1:50.
 Method of bone resorption to remodelling analysis / 2403870
Invention refers to medicine, namely to biochemistry, surgery and dentistry. The bone resorption to remodeling analysis is based on the biochemical blood examination. An the blood coefficient K1 is calculated by formula: K1=[(PTH:A)+(TNF-α:B)+(IL-1β:C)]:3, where PTH is the parathyroid hormone concentration (pg/ml) in the patients, A is the same value in healthy individuals, TNF-α is the level of tumor necrosis factor -α (pg/ml) in the patients, B is the same value in healthy individuals, IL-1β is the interleukin-1β concentration (pg/ml) in the patients, C is the same value in healthy individuals to derive the blood coefficient K2 by formula: K2=[(calcitonin: D) + (osteocalcin: E)]:2, where the calcitonin concentration (ng/ml) in the patients, D is the same value in healthy individuals, the osteocalcin level (ng/ml) in the patients, E is the same value in healthy individuals. Then the bone metabolism control coefficient (BMCC) is calculated by formula BMCC=K1:K2, and the higher BMCC than 1.17, the more intensive resorption prevails over remodelling; and the lower BMCC than 0.83, the more intensive remodelling prevails over resorption.
Method for assessment of kidney function in felines by measurement of ghrelin hormone levels / 2403573
Method for assessment of kidney function in felines includes determination of observed level of ghrelin in tissue or biofluid of feline and establishment of direct dependence of observed level of ghrelin on kidney function by comparison of observed level of ghrelin with reference level of ghrelin that characterises normal kidney function. Method for diagnostics of kidney disease in felines includes detection of observed level of ghrelin in tissue or biofluid of feline and comparison of observed ghrelin level with referent level of ghrelin, which characterises normal kidney function, where observed level lower than reference level indicates kidney disease or predisposition to it. Method for detection of kidney disease beginning in felines includes monitoring level of ghrelin in tissue or biofluid of feline for a certain period of time; where beginning is identified, if at any moment of time level of ghrelin decreases compared to initial level that characterises healthy kidney function. Diagnostics set includes (a) one or more test materials to detect observed levels of ghrelin in tissue or biofluid of feline; and (b) one or more user-available mediums bearing the following information: (i) reference level of ghrelin that corresponds to a specific feline; and (ii) algorithm of direct dependence of observed ghrelin level relative to reference level on kidney function or reverse dependence of observed ghrelin level relative to reference level on availability of kidney disease or predisposition to kidney disease.
Diagnostic technique for foetal maturity / 2399058
There are determined daily excretion of progesterone metabolite - pregnandiol (Pd), foetal steroids - 16α-hydroxy-ethiocholanolone (16α-OH-Et), 16α-hydroxy-androsterone (16α-OH-An), 16α-hydroxy-dihydroepiandrosterone (16α-OH-DHEA) and oestradiol (Oe) in pregnant women on their 37-42 weeks of pregnancy by capillary gas chromatography. A mature foetus is indicated by the following indices: daily Pd excretion is 150.4-348.3 mcmol/24 hour, 16α-OH-Et - 7.9-16.9 mcmol/24 hour, 16α-OH-An - 6.4-12.6 mkmol/24 hour, 16α-OH-DHEA - 15.4-26.1 mcmol/24 hour, Oe - 24.0-38.7 mcmol/24 hour, while an immature foetus show the indices as follows: daily Pd excretion 80.1-150.2 mcmol/24 hour, 16α-OH-Et - 5.8-7.8 mcmol/24 hour, 16α-OH-An - 4.6-6.3 mcmol/24 hour, 16α-OH-DHEA - 10.2-15.3 mcmol/24 hour, and Oe - 14.5-15.6 mcmol/24 hour, and in a overmature foetus, daily Pd excretion, 16α-OH-Et, 16α-OH-An, 16α-OH-DHEA and Oe are considerably lowered and are less than 50.0 mcmol/24 hour, less than 12.0 mcmol/24 hour, less than 5.8 mcmol/24 hour, less than 4.6 mcmol/24 hour, less than 10.2 mcmol/24 hour, respectively.
Method for prediction of clinical course in disseminated skin melanoma patients / 2399057
Method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology.
Method for prediction of effectiveness of neoadjuvant automyelochemotherapy in patients with recurrent breast cancer / 2393484
Prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.
Method for determination severity level of trophological insufficiency in patients with chronic obstructive pulmonary disease / 2390026
Body weight index (BWI) is evaluated; if it is lower than 20 kg/m2, additional analysis is needed to determine the serum leptin concentration. If it is within 16.01±0.64 to 10.15±0.91 ng/ml, the absence of trophological insufficiency is diagnosed, while the values within 5.49±0.46 to 2.26 ng/ml enable to diagnose trophological insufficiency of medium severity, while the values 1.90 to 0.72±0.09 ng/ml indicate severe trophological insufficiency.
Method of forecasting retrocessions of larynx cancer / 2389030
In patients suffering from larynx cancer after surgical oncotomy in the course of dispensary observation levels of androsteron and estradiol in 24-hour collection urine are examined and their ratio to each other are determined. At ratio level more than 3 emergence of disease retrocession or metastasis in the near future is forecasted. At ratio level lower than 3 a long-lasting recurrence-free period is forecasted.
 Diagnostic technique for desynchronosis of hypophysial thyroid system in patients with severe bronchial asthma, previously not taking glucocorticoid therapy / 2382366
Diagnostic technique for desynchronosis of hypophysial thyroid system in the patients with severe bronchial asthma refers to medicine. Substance consists that blood of the patients is radioimmunoassayed for concentration of TSH, T3, T4 hormones. The obtained data are processed to draw a graphic curve of circadian rhythm for each hormone that provides a basis to determine individual acrophase and batiphase time. The acrophase (confidence interval) TSH development biorhythm 9 h 11 min (confidential interval 4 h 57 min to 13 h 26 min), T3 hormone - 15 h 01 min (confidential interval 8 h 05 min to 21 h 57 min) T4 hormone - 16 h 34 min (confidential interval 8 h 55 min to 24 h 13 min), and batiphase of circadian TSH secretion rhythm 21 h to 22 h, T3 - 2 h to 4 h, T4 4 h to 5 h ensure to diagnose apparent desynchronosis of hypophysial thyroid system.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: content of sex hormones -estradiol and progesterone - in blood is determined. After that coefficient of ratio of estradiol concentration to progesterone concentration is calculated. If values of coefficient are within the range from 10 to 221, duration of recurrence-free period from 5 to 13 years is predicted, and if values of coefficient are within the range 367-1295 recurrence-free period for 28-30 months is predicted. EFFECT: application of method makes it possible to predict duration of recurrence-free period in radically treated patients with mammary gland cancer. 1 tbl, 2 ex
The invention relates to medicine, namely to biochemical research in Oncology, and can be used for dynamic monitoring of patients on post stage for the early detection of recurrence and the appointment of adequate treatment. Breast cancer is one of the most common cancers, while in recent years despite the use of modern diagnostic methods of treatment recorded steady, intensive growth as its frequency, and the mortality rate from this disease. Medical statistics show that 50% of patients die within 5 years after treatment from the generalization process. In addition to the development of distant metastases in a significant number of treated women observed local-regional recurrence, the appearance of which in many cases ends with the dissemination of the tumor process - almost 40% of patients with isolated recurrence noted the progression of the disease. These data underscore the need to find an accessible and informative criteria, the use of which during the dynamic observation of patients at post stage could indicate adverse changes homeostasis, contributing to the increased risk of recurrence of breast cancer. Known is a Method for predicting the recurrence of vulvar cancer" (patent No. 2023266 from 15.XI.94, bull. No. 21 from 15.XI.94). The authors of this development has established that the concentration in the serum of patients with this cancer of the hormone prolactin, which is determined before the start of remedial measures is informative with regard to the further course of the disease after the completion of a comprehensive cancer treatment. The study showed that the content of prolactin in the blood, exceeding 400 mm/ml, allows to predict the development of recurrence of vulvar cancer in the next time post of observation. The disadvantage of this method is its development for prediction of disease recurrence in patients with malignant process in the vulva, which excludes the possibility of its application with the same goal in patients with cancer of other localization, including breast cancer. Known "Method of predicting the course of cancer" (Patent No. 2018835 from 11.XI.90. Bull. No. 16 from 30.08.94). As a result of this research was the possibility of predicting the course of malignant process based on the determination of the content in lymphocytes and neutrophils in the blood of the biogenic amine histamine within 4-45 days. Informative is the ratio of the previous index to the next - when it is more about 0,9 will nezirut complication of the disease in the form of strangulation of the patient, the occurrence of relapses and metastases. The disadvantages of this method include, in our opinion, the fact that he assumes the universality of the influence of the tumor on the body regardless of the localization process and the peculiarities of its pathogenesis. While not denying the existence of a common directions in reaction to the development of tumors, more scientifically sound can be considered as the prognosis of the disease, taking into account the current views on the mechanisms of pathogenesis of various malignancies. Known "Method of predicting outcomes of drug therapy in patients with breast cancer", selected as a prototype (Borduchkov YU. et al. M, 1997). The authors suggested before treatment in these patients to determine daily urine six indicators - total content of 17-ketosteroid, dehydroepiandrosterone, etiocholanolone, dopamine, norepinephrine and epinephrine; then the obtained results were subjected to mathematical treatment for the calculation of the discriminant functions, the value of which is used for preliminary evaluation of the results of drug therapy. In addition to the significant complexity of the proposed method for predicting its drawback is the limited application development with objective clinical assessment only neposredno the social impact of drug effects on tumor process. In this regard, the method can not be applied to assess the future direction of the process after completing the full course of complex treatment of patients with breast cancer, and over the next, usually repeated at the given pathology courses of adjuvant chemotherapy. This fact is even more important because, as you know, there is no direct correlation between the degree of immediate effectiveness of drug therapy and individual characteristics of the flow of breast cancer in post stage. For hormone-dependent tumors, such as breast cancer pathogenesis is closely associated with endocrine status of the organism that determines the feasibility of a search for prognostic factors among the indicators of hormonal homeostasis in patients with this pathology. The aim of the invention is the identification of factors predicting the duration of recurrence-free period in patients radically treated for breast cancer. This objective is achieved in that during the dynamic observation of patients with breast cancer in the blood and determine the content of sex hormones - estradiol and progesterone, calculate the ratio of the concentration of estradiol to the concentration of progesterone and when the value of the coefficient in the boundary is from 10 to 221 predict the duration of recurrence-free period from 5 to 13 years and when the values of the coefficient within the boundaries 367-1295 relapse after 28-30 months after radical treatment. The invention of "a Method for predicting the duration of recurrence-free period in radically treated patients with breast cancer" is new, because it is not known from the level of medicine, biochemical studies in Oncology, predicting relapse in post stage of radically treated patients with breast cancer. The novelty of the invention lies in the fact that patients determine the blood levels of sex hormones - estradiol and progesterone, calculate the ratio of the concentration of estradiol to the concentration of progesterone and the coefficient values in the range from 10 to 221 predict the duration of recurrence-free period from 5 to 13 years, and when the values of the coefficient within the boundaries 367-1295 predict relapse-free period during 28-30 months. The invention of "a Method for predicting the duration of recurrence-free period in radically treated patients with breast cancer" is industrially applicable, as may be used in health care facilities, cancer research institutes, breast care clinics and other medical institutions for the treatment of patients with breast cancer. "With the persons of predicting the duration of recurrence-free period in radically treated patients with breast cancer" is as follows. We observed 6 menopausal women who have been diagnosed with a local recurrence of breast cancer (BC), developed at different times after radical treatment of the primary disease. Before the start of remedial measures in the blood of patients determined the content of estradiol and progesterone and estimated individual coefficients of the ratio of their concentrations (estradiol, progesterone). Values of the coefficient of the patients varied significantly, as well as the time intervals from the primary process to relapse. A comparative analysis of both factors was established inverse relationship between the duration of recurrence-free period and the value of the coefficient. Women with its value in the range from 10 to 221 relapse occurred later 5-13 years after primary breast cancer. In contrast, relapse-free period in patients with coefficient 367 and 1295 was much shorter and was 28-30 months. The data presented indicate that higher ratios of concentrations of estradiol and progesterone in the blood of treated breast cancer patients, greater than 300, are one of the most important endogenous factors that contribute to a more rapid emergence of a second process and significantly reduce relapse-free survival of patients. The floor is these results indicate the need for inclusion in the scheme of examination-treated breast cancer patients periodically determine their ratio in blood estradiol and progesterone timely correction therapeutic interventions with increasing ratio between hormones more than 300.
Examples of clinical application "a Method for predicting the duration of recurrence-free period in radically treated patients with breast cancer". Clinical example 1. Patient D., born in 1930, he enrolled in OAT RNII 28.05.07 with what MAGNETOM - cancer of the right breast pT2N0M0 St. IIA, the state after the combined treatment in November 1999, the Metastasis of breast cancer in soft tissue anterior chest wall on the right. CL. gr. 2. The duration of recurrence-free period of 7.5 years. The process cytologically verified (CA No. 11884-85), among lipid droplets found singly or in small groups of atypical cells. The local status before treatment: the right breast p/o scar above which 3 cm in the soft tissues of the anterior chest wall is determined by the tumor of 2.5 cm × 4,0 dense consistency, without distinct outlines, rough, motionless. The ultrasound results: the projection of the soft tissues of the chest to the right, closer to the axillary area, defined hypoechoic formation of irregular shape from 0.7 to 4.5×2 cm (echographically relapse). 29.05.07 in the blood of the patient will determine the content of estriol and progesterone, the ratio between the concentrations of hormones amounted to 208. In the future the patient a course of neoadjuvant chemotherapy followed by resection of the tumor. Thus, the recurrence of breast cancer in patients on background ratio of the concentrations of estradiol and progesterone in the blood equal to 208, has evolved over 7.5 years after primary malignant process. Clinical example 2. Patient D., born in 1954, the post is sludge in OOMT RNII 29.01.07, diagnosed with cancer of the left breast pT2N2M0, St. IIIA. Condition after complex treatment in July 2004. Multiple metastases of breast cancer in the soft tissue of the scar, CL. gr. 2. The duration of recurrence-free period - 30 months. The process in the rumen cytologically verified 16.01.07, CA No. 1114-17 - carcinoma. The local status before treatment: left breast cancer postoperative scar in the soft tissues of which is determined by the tumor to 4.0 cm thick consistency, without distinct outlines, in the middle third p/o scar tumor to 2.0 cm without clear contours, thick consistency. Data ultrasonography before treatment: in the medial part of the postoperative scar hypoechoic education with linear bands, 2.4×3,3 see In the middle third hypoechoic education 1,1 see Regional lymph nodes are not enlarged. Conclusion: recurrence in the projection of the postoperative scar. 30.01.07, estimation of blood the patient the content of estradiol and progesterone, the ratio of the concentrations of hormones amounted to 367. The patient received a course of neoadjuvant chemotherapy followed by resection of the tumor. Thus, the recurrence of breast cancer in a patient, Dr. to background ratio of the concentrations in blood estradiol and progesterone equal to 367, developed through 30 months after p is vicinage malignant process. Technical and economic efficiency of the Method for predicting the duration of recurrence-free period in radically treated patients with breast cancer" is that the factors predicting recurrence-free period associated with endocrine status of the organism. Higher ratios of concentrations of estradiol and progesterone in the blood of treated patients, greater than 300, are one of the most important endogenous factors that contribute to a more rapid emergence of a second process and significantly reduce relapse-free survival of patients. Timely correction of remedial measures must be periodically determining in treated patients with primary breast cancer the ratio of concentrations in blood estradiol and progesterone. A method for predicting the duration of recurrence-free period in radically treated patients with breast cancer, including biochemical, characterized in that before the start of remedial measures in the blood determine the content of sex hormones - estradiol and progesterone, calculate the ratio of the concentration of estradiol to the concentration of progesterone and the coefficient values in the range from 10 to 221 predict the duration of recurrence-free period from 5 to 3 years, and when the values of the coefficient within the boundaries 367-1295 - relapse through 28-30 months after radical treatment.
|
||||||||||||||||||||||